Please login to the form below

Not currently logged in
Email:
Password:

tax inversion

This page shows the latest tax inversion news and features for those working in and with pharma, biotech and healthcare.

Brexit to blame as firm plans to leave UK for Ireland

Brexit to blame as firm plans to leave UK for Ireland

Tax-inversion deal brought company to UK - now Brexit causes a re-think. ... The company has been based in the UK for tax purposes since November 2015, when it completed a $1.9bn ‘tax inversion’takeover of British firm Synergy Health.

Latest news

  • Pfizer names next CEO as Read retires Pfizer names next CEO as Read retires

    In 2014, Pfizer pursued a hostile takeover bid for AstraZeneca, but had to concede defeat after a bruising public battle, the company’s ‘tax inversion’plans being heavily criticised. ... Another tax-inversion based (reverse) merger with Allergan

  • Shire rebuffs Takeda bids, as Allergan bows out Shire rebuffs Takeda bids, as Allergan bows out

    AbbVie offered $55bn for the biopharma in 2014, but the transaction was abandoned after the US introduced new measures to discourage tax inversion deals.

  • Takeda mulls bid for Irish biopharma Shire Takeda mulls bid for Irish biopharma Shire

    That particular deal, which saw AbbVie offer $55bn for the biopharma, came to a halt after the US introduced new measures to discourage tax inversion deals.

  • Shire suffers pipeline failure as takeover speculation builds Shire suffers pipeline failure as takeover speculation builds

    Shire was well on the way to be acquired by AbbVie back in 2014 for £32bn ($43bn), but that deal was scuppered by a US crackdown on tax inversion deals, and ... Changes to US rules on repatriation of overseas cash – part of President Trump’s tax

  • Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

    Right now I believe we need to see tax reform - or the absence of tax reform - to understand what the market values are," he said on a conference call. ... Pfizer walked away from a $160bn merger with Allergan last year, blaming a clampdown on so-called

More from news
Approximately 7 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    curb tax inversion s.

  • A rare talent A rare talent

    took steps to prevent 'tax inversion' mergers.

  • Deal Watch October 2016 Deal Watch October 2016

    years because of the taxman's changes in tax inversion rules.

  • Deal Watch August 2016 Deal Watch August 2016

    In April this year the major news was the collapse of Pfizer's $160bn acquisition of Allergan as a result of change in US tax regulations to prevent tax inversions. ... This can turn into a hostile bid. For example, Pfizer made an unsolicited bid for

  • Deal Watch April 2016 Deal Watch April 2016

    Pfizer's dogged determination to achieve a tax inversion can only be described as a fiasco and given, that this was the second time of trying, perhaps fiascos, is more appropriate. ... Non US countries where Pfizer have parked $80bn. Non-US target

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics